BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25573380)

  • 21. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.
    LaRocca CJ; Han J; Gavrikova T; Armstrong L; Oliveira AR; Shanley R; Vickers SM; Yamamoto M; Davydova J
    Surgery; 2015 May; 157(5):888-98. PubMed ID: 25731784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
    Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
    Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
    Spencer JF; Sagartz JE; Wold WS; Toth K
    Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.
    Yu YA; Galanis C; Woo Y; Chen N; Zhang Q; Fong Y; Szalay AA
    Mol Cancer Ther; 2009 Jan; 8(1):141-51. PubMed ID: 19139123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
    Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
    Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
    Ogura Y; Mizumoto K; Nagai E; Murakami M; Inadome N; Saimura M; Matsumoto K; Nakamura T; Maemondo M; Nukiwa T; Tanaka M
    Cancer Gene Ther; 2006 May; 13(5):520-9. PubMed ID: 16341142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
    Prasad S; Yadav VR; Sung B; Gupta SC; Tyagi AK; Aggarwal BB
    Oncotarget; 2016 Mar; 7(11):13182-96. PubMed ID: 26909608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.
    Watanabe I; Kasuya H; Nomura N; Shikano T; Shirota T; Kanazumi N; Takeda S; Nomoto S; Sugimoto H; Nakao A
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):875-82. PubMed ID: 17726607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.
    Kaliberov SA; Kaliberova LN; Buchsbaum DJ; Curiel DT
    Cancer Gene Ther; 2014 Jul; 21(7):264-74. PubMed ID: 24903014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT.
    Li Y; Hong J; Jung BK; Oh E; Yun CO
    Cancer Lett; 2019 Sep; 459():15-29. PubMed ID: 31150821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
    Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
    Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.
    Bunuales M; Garcia-Aragoncillo E; Casado R; Quetglas JI; Hervas-Stubbs S; Bortolanza S; Benavides-Vallve C; Ortiz-de-Solorzano C; Prieto J; Hernandez-Alcoceba R
    Hum Gene Ther; 2012 Dec; 23(12):1258-68. PubMed ID: 22985305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
    Jia L; Zhang MH; Yuan SZ; Huang WG
    World J Gastroenterol; 2005 Jan; 11(3):447-50. PubMed ID: 15637766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.